An interventional study of Low dose, upright, dedicated breast CT in Breast Cancer Detection, sponsored by University of Arizona. Not yet recruiting. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by University of Arizona · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Breast Neoplasms by University of Arizona — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · University of Arizona.
Among the 32 studies in Breast Neoplasms by University of Arizona, this one is the 10th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 32nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 32 studies in Breast Neoplasms by University of Arizona are open now, in 1 country. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 40+ · Women only · Healthy volunteers
University of Arizona · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 28 across the 28 interventional studies, 83 across the 4 observational. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
3 of the studies in Breast Neoplasms by University of Arizona that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07705100University of ArizonaClinical Feasibility Study of Upright, Low-dose, High-resolution, 3D Breast CT (UBCT). | 2026-12-31 |
| NCT05715255University of ArizonaAdaptive Symptom Self-Management Immunotherapy Study | 2027-04-30 |
| NCT05676255University of ArizonaThe Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Breast Neoplasms by University of Arizona, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators are doing this study to find out if a new kind of breast imaging (called upright dedicated breast CT or UBCT) can help doctors to see the small structures in breast tissue more clearly in 3-D and without overlap.
The breast imaging device that will be used in this study (UBCT) is not FDA-approved, so this is a research study. The machine has been designed to remove mammography-like breast compression and use radiation dose comparable to mammography. The breast CT device will take multiple x-ray pictures of the subjects breast in approximately 20 seconds and create a 3-D image of the breast. It does not compress or squish the breast like a mammogram.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the screening cohort, the inclusion criteria are, women:
For the diagnostic cohort, the inclusion criteria are, women:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women who undergo breast cancer screening using mammography and/or digital breast tomosynthesis.
Device: Low dose, upright, dedicated breast CT
Women who have suspicious finding(s) that require biopsy.
Device: Low dose, upright, dedicated breast CT
This study investigates the feasibility of an upright, dedicated breast CT (UBCT) for breast cancer detection.
Also known as: UBCT
Feasibility of UBCT
The proportion of participants who successfully complete the imaging exam using upright, dedicated breast CT (UBCT).
Time frame: From enrollment to end of study in approximately 6 months.
No study locations are listed for this record.
Plan to share: Undecided — IPD information may be shared with individual academic investigators in accordance with the University of Arizona's data sharing agreement.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 4 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.